JP2006524491A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006524491A5 JP2006524491A5 JP2006503972A JP2006503972A JP2006524491A5 JP 2006524491 A5 JP2006524491 A5 JP 2006524491A5 JP 2006503972 A JP2006503972 A JP 2006503972A JP 2006503972 A JP2006503972 A JP 2006503972A JP 2006524491 A5 JP2006524491 A5 JP 2006524491A5
- Authority
- JP
- Japan
- Prior art keywords
- tropomyosin
- compound
- activity
- binding
- cell surface
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2003901316A AU2003901316A0 (en) | 2003-03-21 | 2003-03-21 | Regulation of cell surface proteins |
| PCT/AU2004/000358 WO2004082690A1 (en) | 2003-03-21 | 2004-03-22 | Regulation of cell surface proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006524491A JP2006524491A (ja) | 2006-11-02 |
| JP2006524491A5 true JP2006524491A5 (enExample) | 2007-05-24 |
Family
ID=31500359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006503972A Withdrawn JP2006524491A (ja) | 2003-03-21 | 2004-03-22 | 細胞表面タンパク質の調節 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20060263781A1 (enExample) |
| EP (1) | EP1622626A1 (enExample) |
| JP (1) | JP2006524491A (enExample) |
| CN (1) | CN1761472A (enExample) |
| AU (1) | AU2003901316A0 (enExample) |
| CA (1) | CA2517186A1 (enExample) |
| WO (1) | WO2004082690A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5140218B2 (ja) | 2001-09-14 | 2013-02-06 | 有限会社コヒーレントテクノロジー | 表面洗浄・表面処理に適した帯電アノード水の製造用電解槽及びその製造法、並びに使用方法 |
| AU2002353060A1 (en) | 2001-12-05 | 2003-06-17 | Oculus Innovative Sciences, Inc. | Method and apparatus for producing negative and positive oxidative reductive potential (orp) water |
| US9168318B2 (en) | 2003-12-30 | 2015-10-27 | Oculus Innovative Sciences, Inc. | Oxidative reductive potential water solution and methods of using the same |
| WO2006102680A2 (en) | 2005-03-23 | 2006-09-28 | Oculus Innovative Sciences, Inc. | Method of treating second and third degree burns using oxidative reductive potential water solution |
| JP5907645B2 (ja) | 2005-05-02 | 2016-04-26 | オキュラス イノヴェイティヴ サイエンシズ、インコーポレイテッド | 歯科用途における酸化還元電位水溶液の使用法 |
| BRPI0706677A2 (pt) | 2006-01-20 | 2011-04-05 | Oculus Innovative Sciences Inc | métodos de tratamento ou prevenção de sinusite com solução aquosa com potencial de oxirredução |
| CA2682744C (en) * | 2007-04-16 | 2015-10-06 | Momenta Pharmaceuticals, Inc. | Methods related to cell surface glyosylation |
| WO2010148004A1 (en) | 2009-06-15 | 2010-12-23 | Oculus Innovative Sciences, Inc. | Solution containing hypochlorous acid and methods of using same |
| ES2529442T3 (es) * | 2010-09-28 | 2015-02-20 | Abera Bioscience Ab | Proteína de fusión para la expresión de proteínas secretoras |
| EP3873453A4 (en) * | 2018-10-30 | 2022-08-03 | University of Florida Research Foundation, Incorporated | AMINO ACID COMPOSITIONS AND METHODS OF TREATMENT OF CF |
| CN111175431A (zh) * | 2020-01-15 | 2020-05-19 | 上海林志生物科技有限公司 | 一种用于肺癌诊断的靶蛋白及其用途、试剂盒 |
| CN113588942B (zh) * | 2021-07-01 | 2022-04-19 | 浙江大学 | 一种检测抗原肌球蛋白1-IgG抗体的试剂盒 |
-
2003
- 2003-03-21 AU AU2003901316A patent/AU2003901316A0/en not_active Abandoned
-
2004
- 2004-03-22 CA CA002517186A patent/CA2517186A1/en not_active Abandoned
- 2004-03-22 US US10/549,301 patent/US20060263781A1/en not_active Abandoned
- 2004-03-22 JP JP2006503972A patent/JP2006524491A/ja not_active Withdrawn
- 2004-03-22 CN CNA2004800077366A patent/CN1761472A/zh active Pending
- 2004-03-22 WO PCT/AU2004/000358 patent/WO2004082690A1/en not_active Ceased
- 2004-03-22 EP EP04722197A patent/EP1622626A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Goh et al. | The protein kinase PKR is required for p38 MAPK activation and the innate immune response to bacterial endotoxin | |
| Bivalacqua et al. | Overexpression of arginase in the aged mouse penis impairs erectile function and decreases eNOS activity: influence of in vivo gene therapy of anti-arginase | |
| US9238042B2 (en) | Antisense modulation of interleukins 17 and 23 signaling | |
| CN101573446B (zh) | 针对中期因子的适体及其应用 | |
| JP6141018B2 (ja) | 炎症性障害を治療するための分子 | |
| CN112040988A (zh) | 修饰的aav衣壳多肽用于治疗肌肉疾病 | |
| US20110111493A1 (en) | Compositions and Methods For Inhibiting Expression Of A Target Gene | |
| Shin et al. | Intratracheally administered LNA gapmer antisense oligonucleotides induce robust gene silencing in mouse lung fibroblasts | |
| CN113677706B (zh) | 肝毒性的治疗 | |
| JP2010521978A5 (enExample) | ||
| CN120500349A (zh) | 包含抗体切割酶的组合物及其使用方法 | |
| JP2021531038A5 (enExample) | ||
| McCollum et al. | Safety and biodistribution of nanoligomers targeting the SARS-CoV-2 genome for the treatment of COVID-19 | |
| CN108642069A (zh) | 一种三疣梭子蟹comt基因及其应用 | |
| JP2010536365A5 (enExample) | ||
| US20260132406A1 (en) | RNAi Agents for Inhibiting Expression of Activin Receptor-Like Kinase 7 (ALK7), Compositions Thereof, and Methods of Use | |
| WO2016079321A1 (en) | Antagonists of setdb2 for use in the therapy of infectious diseases | |
| US20260009037A1 (en) | RNAi Agents for Inhibiting Expression of Mitochondrial Amidoxime Reducing Component 1 (MARC1), Pharmaceutical Compositions Thereof, and Methods of Use | |
| JP2007523658A (ja) | アレルギー性疾患を治療するための物質および方法 | |
| US20240392295A1 (en) | Treatment of mst1 related diseases and disorders | |
| JP7626423B6 (ja) | 線維症治療薬 | |
| Shaabani et al. | ISG15 drives immune pathology and respiratory failure during systemic lymphocytic choriomeningitis virus infection | |
| WO2005104785A3 (en) | Methods and compositions for specifically targeting human hepatocellular carcinoma cells | |
| Uemura et al. | Short polymers of arginine rapidly translocate into vascular cells effects on nitric oxide synthesis | |
| ATE500840T1 (de) | Verwendung von gilz-protein zur modulation einer antigenspezifischen immunantwort |